Rheumatology International

, Volume 32, Issue 4, pp 1095–1097

Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF

Letter to the Editor


Familial mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever, peritonitis, pleuritis, and genetically by autosomal recessive inheritance. The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine. About 5–10% of cases with familial mediterranean fever may be resistant to colchicine. In literature, there is a controversy about the treatment of FMF patients resistant to colchicine. We describe a case with FMF, proteinuria, and bilateral sacroiliitis, which responded to anti-TNF (tumor necrosis factor)-alpha therapy with infliximab and etanercept.


Familial mediterranean fever (FMF) Proteinuria Anti-TNF (tumor necrosis factor) alpha treatment 


  1. 1.
    Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S (2007) Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial mediterranean fever. Intern Med 46(15):1247–1249PubMedCrossRefGoogle Scholar
  2. 2.
    El-Shanti HI (2003) Familial mediterranean fever and renal disease. Saudi J Kidney Dis Transpl 14(3):378–385PubMedGoogle Scholar
  3. 3.
    Ben-Chetrit E, Levy M (1998) Familial mediterranean fever. Lancet 351:659–664PubMedCrossRefGoogle Scholar
  4. 4.
    Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R, Langevitz P, Livneh A (2004) Colchicine nonresponsiveness in familial mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Arthritis Rheum 33(4):273–282CrossRefGoogle Scholar
  5. 5.
    Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R (2001) The musculoskeletal manifestations of familial mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum 44(6):1416–1419PubMedCrossRefGoogle Scholar
  6. 6.
    Incel NA, Saracoglu M, Erdem HR (2003) Seronegative spondiloarthropathy of familial mediterranean fever. Rheum Int 23(1):41–43Google Scholar
  7. 7.
    Ozen S, Bakkaloglu A, Yilmaz E, Duzova A, Balci B, Topaloglu R, Besbas N (2003) Mutations in the gene for familial mediterranean fever: do they predispose to inflammation. J Rheum 30(9):2014–2018PubMedGoogle Scholar
  8. 8.
    Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR (2004) Infliximab treatment of familial mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheum 10(3):134–137CrossRefGoogle Scholar
  9. 9.
    Sakallioglu O, Duzova A, Ozen S (2006) Etanercept in the treatment of arthritis in a patient with familial mediterranean fever. Clin Exp Rheumatol 24:435–437PubMedGoogle Scholar
  10. 10.
    Ozgocmen S, Ozçakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A (2006) Familial Mediterranean sfever responds well to infliximab: single case experience. Clin Rheumatol 25:83–87PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Division of RheumatologyAtatürk Education and Research HospitalAnkaraTurkey
  2. 2.Department of NeurosurgeryAnkara Onkoloji Education and Research HospitalAnkaraTurkey
  3. 3.Division of NephrologyAtatürk Education and Research HospitalAnkaraTurkey

Personalised recommendations